Allison W Kurian

List of Publications by Year
in descending order

313 papers	13,297 citations	20797 60 h-index	28275 105 g-index
318 all docs	318 docs citations	318 times ranked	15314 citing authors

#	Article	IF	Citations
1	Influence of payer coverage and outâ€ofâ€pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. Journal of Genetic Counseling, 2022, 31, 130-139.	0.9	13
2	Association of Genetic Testing Results With Mortality Among Women With Breast Cancer or Ovarian Cancer. Journal of the National Cancer Institute, 2022, 114, 245-253.	3.0	5
3	Greater financial toxicity relates to greater distress and worse quality of life among breast and gynecologic cancer survivors. Psycho-Oncology, 2022, 31, 9-20.	1.0	29
4	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	2.0	6
5	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
6	Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations. JNCI Cancer Spectrum, 2022, 6, .	1.4	1
7	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	2.2	15
8	Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants. JAMA Oncology, 2022, 8, 587.	3.4	36
9	Abstract P2-11-21: Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model. Cancer Research, 2022, 82, P2-11-21-P2-11-21.	0.4	0
10	Polygenic risk scores for prediction of breast cancer risk in Asian populations. Genetics in Medicine, 2022, 24, 586-600.	1.1	27
11	Trends in Annual Surveillance Mammography Participation Among Breast Cancer Survivors From 2004 to 2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 379-386.e9.	2.3	1
12	Weight is More Informative than Body Mass Index for Predicting Postmenopausal Breast Cancer Risk: Prospective Family Study Cohort (ProF-SC). Cancer Prevention Research, 2022, 15, 185-191.	0.7	4
13	Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics. Cancer Medicine, 2022, 11, 297-307.	1.3	2
14	Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. Breast Cancer Research, 2022, 24, 27.	2.2	15
15	Relevance of the MHC region for breast cancer susceptibility in Asians. Breast Cancer, 2022, 29, 869-879.	1.3	1
16	Association of illness mindsets with health-related quality of life in cancer survivors.. Health Psychology, 2022, 41, 389-395.	1.3	4
17	Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. Cancers, 2022, 14, 2716.	1.7	10
18	Breast cancer diagnosis and treatment during the COVID-19 pandemic in a nationwide, insured population. Breast Cancer Research and Treatment, 2022, 194, 475-482.	1.1	14

#	Article	IF	Citations
19	Harnessing artificial intelligence to automate delineation of volumetric breast cancers from magnetic resonance imaging to improve tumor characterization.. Journal of Clinical Oncology, 2022, 40, 597-597.	0.8	0
20	Simulation modeling as a tool to support clinical guidelines and care for breast cancer prevention and early detection in high-risk women.. Journal of Clinical Oncology, 2022, 40, 10525-10525.	0.8	0
21	National claims data analysis of outcomes of hospitalized cancer patients without COVID-19 infection during versus prior to the COVID-19 pandemic.. Journal of Clinical Oncology, 2022, 40, e18679-e18679.	0.8	0
22	A case-control study of healthcare disparities in sex and gender minority patients with breast cancer.. Journal of Clinical Oncology, 2022, 40, 6517-6517.	0.8	1
23	Radiomic features quantifying pixel-level characteristics of breast tumors from magnetic resonance imaging predict risk factors in triple-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, e12612-e12612.	0.8	0
24	A pilot study to increase cascade genetic testing in families with hereditary cancer syndromes.. Journal of Clinical Oncology, 2022, 40, 10602-10602.	0.8	0
25	Ancestry-specific risk of triple-negative breast cancer (TNBC) associated with germline pathogenic variants (PV) in hereditary cancer (CA) predisposition genes.. Journal of Clinical Oncology, 2022, 40, 10517-10517.	0.8	0
26	Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in U.S. women, 2000-2017.. Journal of Clinical Oncology, 2022, 40, 1008-1008.	0.8	3
27	Association of germline genetic testing results with chemotherapy regimens received by women with early-stage breast cancer.. Journal of Clinical Oncology, 2022, 40, 10518-10518.	0.8	1
28	Constitutional BRCA1 methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer.. Journal of Clinical Oncology, 2022, 40, 10509-10509.	0.8	1
29	Symptoms and survivorship needs differences between â€œgood sleepersâ€•and â€œbad sleepersâ€•in survivors of breast and gynecologic cancers. Sleep Medicine, 2022, 100, 49-55.	0.8	1
30	Patterns of social media use and associations with psychosocial outcomes among breast and gynecologic cancer survivors. Journal of Cancer Survivorship, 2021, 15, 677-684.	1.5	4
31	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 329-337.	3.0	45
32	Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes. JNCI Cancer Spectrum, 2021, 5, pkaa083.	1.4	3
33	Comparing 5-Year and Lifetime Risks of Breast CancerÂusing the Prospective Family Study Cohort. Journal of the National Cancer Institute, 2021, 113, 785-791.	3.0	13
34	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854.	2.9	5
35	Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling. Journal of the National Cancer Institute, 2021, 113, 1484-1494.	3.0	92
36	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19

#	Article	IF	Citations
37	A Population-Based Study of Genes Previously Implicated in Breast Cancer. New England Journal of Medicine, 2021, 384, 440-451.	13.9	414
38	Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants. JAMA Oncology, 2021, 7, 585-592.	3.4	16
39	Benchmark Method for Cost Computations Across Health Care Systems: Cost of Care per Patient per Day in Breast Cancer Care. JCO Oncology Practice, 2021, 17, e1403-e1412.	1.4	3
40	Limited English Proficiency and Disparities in Health Care Engagement Among Patients With Breast Cancer. JCO Oncology Practice, 2021, 17, e1837-e1845.	1.4	13
41	Development and Use of Natural Language Processing for Identification of Distant Cancer Recurrence and Sites of Distant Recurrence Using Unstructured Electronic Health Record Data. JCO Clinical Cancer Informatics, 2021, 5, 469-478.	1.0	14
42	Financing of germline testing: implications for availability and access. Molecular Genetics and Metabolism, 2021, 132, S330-S331.	0.5	0
43	Treatment and Monitoring Variability in US Metastatic Breast Cancer Care. JCO Clinical Cancer Informatics, 2021, 5, 600-614.	1.0	5
44	Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. Journal of Clinical Oncology, 2021, 39, 1631-1640.	0.8	62
45	Multicancer hereditary syndrome testing: Genetic counselorsâ€™ perspectives.. Journal of Clinical Oncology, 2021, 39, 10594-10594.	0.8	0
46	Cancer-specific mortality associated with germline genetic testing results among women with breast cancer or ovarian cancer treated with chemotherapy.. Journal of Clinical Oncology, 2021, 39, 10517-10517.	0.8	0
47	Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.. Journal of Clinical Oncology, 2021, 39, 10531-10531.	0.8	0
48	Impact of disruptions in breast cancer control due to the COVID-19 pandemic on breast cancer mortality in the United States: Estimates from collaborative simulation modeling.. Journal of Clinical Oncology, 2021, 39, 6562-6562.	0.8	0
49	Breast cancer screening for carriers of ATM, CHEK2, and PALB2 pathogenic variants: A comparative modeling analysis.. Journal of Clinical Oncology, 2021, 39, 10500-10500.	0.8	0
50	Weakly supervised temporal model for prediction of breast cancer distant recurrence. Scientific Reports, 2021, 11, 9461.	1.6	11
51	A simulation model-based clinical decision tool to guide personalized treatment based on individual characteristics: Does 21-gene recurrence score assay testing change decisions?. Journal of Clinical Oncology, 2021, 39, e12507-e12507.	0.8	0
52	Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. JCO Precision Oncology, 2021, 5, 1073-1081.	1.5	9
53	Receipt of guidelineâ€concordant care among young adult women with breast cancer. Cancer, 2021, 127, 3325-3333.	2.0	3
54	Tobacco Smoking and Risk of Second Primary Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 968-979.	0.5	54

#	Article	IF	Citations
55	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	2.6	6
56	Performance of the IBIS/Tyrerâ€Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative. Cancer, 2021, 127, 3742-3750.	2.0	21
57	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	2.2	7
58	Widening cancer care disparities in the adoption of telemedicine during COVID 19: who is left behind?. Gynecologic Oncology, 2021, 162, S23.	0.6	2
59	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	2.9	9
60	Genetic insights into biological mechanisms governing human ovarian ageing. Nature, 2021, 596, 393-397.	13.7	183
61	Development of a Mobile Health App (TOGETHERCare) to Reduce Cancer Care Partner Burden: Product Design Study. JMIR Formative Research, 2021, 5, e22608.	0.7	9
62	Development and Validation of a Simulation Modelâ€"Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions. Journal of Clinical Oncology, 2021, 39, 2893-2902.	0.8	7
63	The Impact of COVID-19 on Patients With Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 580-587.	0.6	26
64	Impact of Low-Dose Computed Tomography Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. Journal of Thoracic Oncology, 2021, 16, 1479-1489.	0.5	2
65	Multicancer hereditary syndrome testing: Genetic counselorsâ€™ perspectives.. Journal of Clinical Oncology, 2021, 39, 106-106.	0.8	1
66	Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated (ATM) Gene are Associated with High and Moderate Risks for Multiple Cancers. Cancer Prevention Research, 2021, 14, 433-440.	0.7	68
67	Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing. JCO Precision Oncology, 2021, 5, 307-316.	1.5	18
68	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 77-102.	2.3	498
69	Prevalence of Lynch syndrome in women with mismatch repairâ€deficient ovarian cancer. Cancer Medicine, 2021, 10, 1012-1017.	1.3	12
70	Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. Cancer, 2021, 127, 1275-1285.	2.0	21
71	Reply to Ritzwoller et al. JCO Clinical Cancer Informatics, 2021, 5, 1026-1027.	1.0	0
72	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Scientific Reports, 2021, 11, 19787.	1.6	2

#	Article	IF	Citations
73	Multiple imputation with missing data indicators. Statistical Methods in Medical Research, 2021, 30, 2685-2700.	0.7	30
74	Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. Journal of Clinical Oncology, 2021, 39, 3918-3926.	0.8	22
75	Racial/Ethnic Disparities in Survival after Breast Cancer Diagnosis by Estrogen and Progesterone Receptor Status: A Pooled Analysis. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 351-363.	1.1	7
76	Racial/ethnic differences in cancer diagnosed after metastasis: absolute burden and deaths potentially avoidable through earlier detection. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0823.2021.	1.1	7
77	Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes. JCO Precision Oncology, 2021, 5, 1853-1859.	1.5	2
78	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. JNCI Cancer Spectrum, 2021, 5, pkab090.	1.4	1
79	Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer. JCO Oncology Practice, 2020, 16, e37-e55.	1.4	16
80	Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015. Cancer, 2020, 126, 958-970.	2.0	11
81	European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. Nature Communications, 2020, 11, 3833.	5.8	88
82	Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. JAMA Network Open, 2020, 3, e208501.	2.8	79
83	Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Womenâ€"Reply. JAMA - Journal of the American Medical Association, 2020, 324, 397.	3.8	0
84	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	2.6	39
85	Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer. JAMA Network Open, 2020, 3, e2019452.	2.8	76
86	Projected Reductions in Absolute Cancerâ€"Related Deaths from Diagnosing Cancers Before Metastasis, 2006â€"2015. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 895-902.	1.1	36
87	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	1.6	2
88	Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk. JCO Precision Oncology, 2020, 4, 585-592.	1.5	41
89	Hospital Characteristics and Breast Cancer Survival in the California Breast Cancer Survivorship Consortium. JCO Oncology Practice, 2020, 16, e517-e528.	1.4	6
90	Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 995.	3.8	26

#	Article	IF	Citations
91	Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. Nature Communications, 2020, 11, 1217.	5.8	46
92	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
93	Emerging Opportunity of Cascade Genetic Testing for Population-Wide Cancer Prevention and Control. Journal of Clinical Oncology, 2020, 38, 1371-1374.	0.8	18
94	Health Disparities in Germline Genetic Testing for Cancer Susceptibility. Current Breast Cancer Reports, 2020, 12, 51-58.	0.5	6
95	Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer. JAMA Oncology, 2020, 6, e196400.	3.4	32
96	Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. Value in Health, 2020, 23, 551-558.	0.1	9
97	A case of a transâ€masculine patient receiving testosterone with a history of estrogen receptorâ€positive breast cancer. Breast Journal, 2020, 26, 1888-1889.	0.4	5
98	Abstract P3-07-01: Breast cancer-specific mortality (BCSM) in patients age 50 years or younger with node-positive (N+) breast cancer (BC) treated based on the 21-gene assay in clinical practice. Cancer Research, 2020, 80, P3-07-01-P3-07-01.	0.4	2
99	Performance of the IBIS/Tyrer-Cuzick (TC) Model by race/ethnicity in the Womenâ€™s Health Initiative.. Journal of Clinical Oncology, 2020, 38, 1503-1503.	0.8	2
100	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	2.3	314
101	Abstract P6-08-02: 21-gene recurrence score results according to germline pathogenic variants inBRCA1, BRCA2, PALB2, ATM, CHEK2and Lynch Syndrome genes. , 2020, , .		0
102	Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer.. Journal of Clinical Oncology, 2020, 38, 7063-7063.	0.8	0
103	Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS) and the Tyrer-Cuzick (TC) model.. Journal of Clinical Oncology, 2020, 38, 1504-1504.	0.8	0
104	Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants.. Journal of Clinical Oncology, 2020, 38, 1549-1549.	0.8	2
105	Real-world outcomes of patients with metastatic breast cancer (BC) treated with osteoclast inhibitors (OIs).. Journal of Clinical Oncology, 2020, 38, e19314-e19314.	0.8	0
106	Development and validation of natural language processing (NLP) algorithm for detection of distant versus local breast cancer recurrence and metastatic site.. Journal of Clinical Oncology, 2020, 38, 2043-2043.	0.8	1
107	Abstract IA50: Genetic testing, treatment and mortality after diagnosis of breast cancer or ovarian cancer: The SEER-GeneLINK Initiative. , 2020, , .		0
108	Abstract 2033: Reducing cancer caregiver burden: A user-centered design approach for an mHealth app. , 2020, , .		0

#	Article	IF	Citations
109	Reply to Residual confounding threatens the validity of observational studies on breast cancer local therapy. Cancer, 2020, 126, 2317-2318.	2.0	0
110	Abstract P5-03-02: Cancer risks associated with pathogenic variants in the ataxia telangiectasia mutated (ATM) gene. , 2020, , .		0
111	Abstract P6-08-07: Polygenic breast cancer risk modification in carriers of high and intermediate risk gene mutations. , 2020, , .		0
112	Trends in germline genetic testing and results into survivorship for women diagnosed with breast cancer or ovarian cancer, 2013 to 2017.. Journal of Clinical Oncology, 2020, 38, 273-273.	0.8	0
113	Genomic landscape of ductal carcinoma in situ and association with progression. Breast Cancer Research and Treatment, 2019, 178, 307-316.	1.1	17
114	Chromatin Remodeling in Response to BRCA2-Crisis. Cell Reports, 2019, 28, 2182-2193.e6.	2.9	6
115	Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. JCO Precision Oncology, 2019, 3, 1-12.	1.5	23
116	Patient-clinician interactions and disparities in breast cancer care: the equality in breast cancer care study. Journal of Cancer Survivorship, 2019, 13, 968-980.	1.5	14
117	Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data. JAMIA Open, 2019, 2, 528-537.	1.0	40
118	Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. EBioMedicine, 2019, 48, 203-211.	2.7	14
119	Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. JNCI Cancer Spectrum, 2019, 3, pkz062.	1.4	2
120	Primary care providerâ€“reported involvement in breast cancer treatment decisions. Cancer, 2019, 125, 1815-1822.	2.0	12
121	Is Breast Cancer in Asian and Asian American Women a Different Disease?. Journal of the National Cancer Institute, 2019, 111, 1243-1244.	3.0	17
122	Response to Peshkin, Isaacs, and Schwartz. Journal of the National Cancer Institute, 2019, 111, 874-874.	3.0	0
123	Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. Journal of Clinical Oncology, 2019, 37, 1305-1315.	0.8	266
124	Automatic inference of BI-RADS final assessment categories from narrative mammography report findings. Journal of Biomedical Informatics, 2019, 92, 103137.	2.5	14
125	Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer. Journal of Comparative Effectiveness Research, 2019, 8, 1173-1185.	0.6	3
126	Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits?. Personalized Medicine, 2019, 16, 365-367.	0.8	0

#	Article	IF	Citations
127	Natural Language Processing Approaches to Detect the Timeline of Metastatic Recurrence of Breast Cancer. JCO Clinical Cancer Informatics, 2019, 3, 1-12.	1.0	43
128	Guidelines Do Not Proscribe Surgeons Performing Genetic Testingâ€"Reply. JAMA Surgery, 2019, 154, 269.	2.2	0
129	Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer. Cancer, 2019, 125, 943-951.	2.0	15
130	Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative. Journal of the National Cancer Institute, 2019, 111, 95-98.	3.0	81
131	Preventive surgery after multiplex genetic panel testing (MGPT).. Journal of Clinical Oncology, 2019, 37, 1525-1525.	0.8	1
132	Breast cancer treatment according to pathogenic variants in cancer susceptibility genes in a population-based cohort.. Journal of Clinical Oncology, 2019, 37, 560-560.	0.8	2
133	Oncotype DX DCIS use and clinical utility: A SEER population-based study.. Journal of Clinical Oncology, 2019, 37, e12046-e12046.	0.8	1
134	Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptorâ^'Positive Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 662-668.	2.3	14
135	Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Womenâ€™s Health Initiative.. Journal of Clinical Oncology, 2019, 37, 1513-1513.	0.8	0
136	Radiomics features to identify distinct subtypes of triple-negative breast cancers.. Journal of Clinical Oncology, 2019, 37, 3069-3069.	0.8	0
137	Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians.. Journal of Clinical Oncology, 2019, 37, 6531-6531.	0.8	1
138	Differences among Asian/Asian American, and Caucasian breast and gynecologic cancer patient-reported survivorship needs, symptoms, and illness mindsets (N=220).. Journal of Clinical Oncology, 2019, 37, 11620-11620.	0.8	0
139	Adherence to breast cancer treatment guidelines according to pathogenic variants in cancer susceptibility genes in a population-based cohort.. Journal of Clinical Oncology, 2019, 37, 34-34.	0.8	0
140	Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1237-1245.	0.4	10
141	Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. JAMA - Journal of the American Medical Association, 2018, 319, 154.	3.8	209
142	Recent Trends in Chemotherapy Use and Oncologistsâ€™ Treatment Recommendations for Early-Stage Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 493-500.	3.0	50
143	Intratumoral Spatial Heterogeneity at Perfusion MR Imaging Predicts Recurrence-free Survival in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy. Radiology, 2018, 288, 26-35.	3.6	102
144	Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling. Medical Decision Making, 2018, 38, 9S-23S.	1.2	37

#	Article	IF	Citations
145	Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 619-626.	1.1	341
146	Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research, 2018, 24, 2851-2858.	3.2	65
147	What Factors Influence Womenâ€™s Perceptions of their Systemic Recurrence Risk after Breast Cancer Treatment?. Medical Decision Making, 2018, 38, 95-106.	1.2	8
148	Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genetics in Medicine, 2018, 20, 234-239.	1.1	131
149	Association of Germline Genetic Test Type and Results With Patient Cancer Worry After Diagnosis of Breast Cancer. JCO Precision Oncology, 2018, 2018, 1-8.	1.5	9
150	Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. Journal of Clinical Oncology, 2018, 36, 1218-1224.	0.8	59
151	Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. Oncotarget, 2018, 9, 7832-7843.	0.8	9
152	Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?. JCO Precision Oncology, 2018, 2, 1-10.	1.5	7
153	Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. JNCI Cancer Spectrum, 2018, 2, pky062.	1.4	199
154	Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancerâ€”Reply. JAMA Oncology, 2018, 4, 1788.	3.4	1
155	Patient communication of cancer genetic test results in a diverse population. Translational Behavioral Medicine, 2018, 8, 85-94.	1.2	34
156	Knowledge regarding and patterns of genetic testing in patients newly diagnosed with breast cancer participating in the iCanDecide trial. Cancer, 2018, 124, 4000-4009.	2.0	6
157	Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1332-1341.	1.1	28
158	Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer. JAMA Surgery, 2018, 153, 909.	2.2	22
159	Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer. Cancer, 2018, 124, 3668-3676.	2.0	118
160	From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value in Health, 2018, 21, 1062-1068.	0.1	19
161	Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy. International Journal of Cancer, 2018, 143, 3262-3272.	2.3	18
162	Measuring serum melatonin in postmenopausal women: Implications for epidemiologic studies and breast cancer studies. PLoS ONE, 2018, 13, e0195666.	1.1	5

#	Article	IF	Citations
163	Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. JAMA Oncology, 2018, 4, 1066.	3.4	146
164	Macrophages Promote Circulating Tumor Cellâ€“Mediated Local Recurrence following Radiotherapy in Immunosuppressed Patients. Cancer Research, 2018, 78, 4241-4252.	0.4	36
165	Unmet need for clinician engagement about financial toxicity after diagnosis of breast cancer.. Journal of Clinical Oncology, 2018, 36, 10080-10080.	0.8	1
166	Computing the cost of care per day of breast cancer survivor care.. Journal of Clinical Oncology, 2018, 36, 10-10.	0.8	1
167	Promoting colorectal cancer (CRC) screening after multiplex genetic testing and genetic counseling.. Journal of Clinical Oncology, 2018, 36, 1582-1582.	0.8	0
168	Genetic testing and results in population-based breast cancer patients and ovarian cancer patients.. Journal of Clinical Oncology, 2018, 36, 1578-1578.	0.8	0
169	Promoting breast cancer screening after multiplex genetic panel testing (MGPT) and genetic counseling.. Journal of Clinical Oncology, 2018, 36, 1581-1581.	0.8	0
170	The impact of doctorâ€“patient communication on patientsâ€™ perceptions of their risk of breast cancer recurrence. Breast Cancer Research and Treatment, 2017, 161, 525-535.	1.1	34
171	Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. Clinical Cancer Research, 2017, 23, 3365-3370.	3.2	55
172	Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways. Clinical Cancer Research, 2017, 23, 3334-3342.	3.2	80
173	Treatmentâ€associated toxicities reported by patients with earlyâ€stage invasive breast cancer. Cancer, 2017, 123, 1925-1934.	2.0	68
174	Dynamic strategy for personalized medicine: An application to metastatic breast cancer. Journal of Biomedical Informatics, 2017, 68, 50-57.	2.5	10
175	Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 531.	3.8	103
176	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 9-20.	2.3	408
177	The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition. Current Treatment Options in Oncology, 2017, 18, 27.	1.3	25
178	Trends in Reoperation After Initial Lumpectomy for Breast Cancer. JAMA Oncology, 2017, 3, 1352.	3.4	100
179	Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 219-228.	2.3	35
180	Reply to Comment on â€˜Statin use and all-cancer survival: prospective results from the Womenâ€™s Health Initiativeâ€™. British Journal of Cancer, 2017, 116, e2-e2.	2.9	1

#	Article	IF	Citations
181	Recurrence risk perception and quality of life following treatment of breast cancer. Breast Cancer Research and Treatment, 2017, 161, 557-565.	1.1	51
182	The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients. Breast Cancer Research and Treatment, 2017, 161, 587-595.	1.1	8
183	Second Opinions From Medical Oncologists for Early-Stage Breast Cancer. JAMA Oncology, 2017, 3, 391.	3.4	22
184	Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer. JAMA Surgery, 2017, 152, 274.	2.2	107
185	Synergistic drug combinations from electronic health records and gene expression. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 565-576.	2.2	9
186	Treatment decisions and employment of breast cancer patients: Results of a populationâ€based survey. Cancer, 2017, 123, 4791-4799.	2.0	51
187	Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California. American Journal of Clinical Pathology, 2017, 148, 199-207.	0.4	9
188	Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer. Radiology, 2017, 285, 401-413.	3.6	92
189	Rising Bilateral Mastectomy Rates Among Neoadjuvant Chemotherapy Recipients in California From 1998 to 2012. Annals of Surgery, 2017, 266, 353-360.	2.1	9
190	Oncologistsâ€™ influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer?. Breast Cancer Research and Treatment, 2017, 165, 751-756.	1.1	7
191	Chemotherapy decisions and patient experience with the recurrence score assay for earlyâ€stage breast cancer. Cancer, 2017, 123, 43-51.	2.0	17
192	Linking Electronic Health Records to Better Understand Breast Cancer Patient Pathways Within and Between Two Health Systems. EGEMS (Washington, DC), 2017, 3, 5.	2.0	24
193	Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. Journal of Clinical Oncology, 2017, 35, 2232-2239.	0.8	212
194	Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. JCO Precision Oncology, 2017, 1, 1-12.	1.5	96
195	Pathogenic germline mutations in emerging cancer genes: What happens after panel testing?. Journal of Clinical Oncology, 2017, 35, 1528-1528.	0.8	1
196	Gaps in integrating genetic testing into management of breast cancer.. Journal of Clinical Oncology, 2017, 35, 160-160.	0.8	1
197	Recent time trends in chemotherapy use and oncologists' chemotherapy recommendations for early-stage, hormone receptor-positive breast cancer.. Journal of Clinical Oncology, 2017, 35, 541-541.	0.8	0
198	Factors associated with 21-gene assay receipt among women with lymph node positive breast cancer.. Journal of Clinical Oncology, 2017, 35, 6554-6554.	0.8	0

#	Article	IF	Citations
199	Treatment decisions and employment of breast cancer patients: Results of a population-based survey.. Journal of Clinical Oncology, 2017, 35, 10052-10052.	0.8	0
200	Expanded yield of multiplex panel testing in fully accrued prospective trial.. Journal of Clinical Oncology, 2017, 35, 1525-1525.	0.8	0
201	Performance of mutation risk prediction models in a racially diverse multi-gene panel testing cohort.. Journal of Clinical Oncology, 2017, 35, 1523-1523.	0.8	0
202	Safety of multiplex gene testing for inherited cancer risk in a fully accrued prospective trial.. Journal of Clinical Oncology, 2017, 35, 1576-1576.	0.8	0
203	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 44-56.	1.8	19
204	Addressing inherited predisposition for breast cancer in transplant recipients. Journal of Surgical Oncology, 2016, 113, 605-608.	0.8	1
205	Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 153-162.	2.3	153
206	Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems. Journal of Oncology Practice, 2016, 12, e697-e709.	2.5	12
207	The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1064-1072.	1.1	20
208	Validation of self-reported comorbidity status of breast cancer patients with medical records: the California Breast Cancer Survivorship Consortium (CBCSC). Cancer Causes and Control, 2016, 27, 391-401.	0.8	13
209	Genetics of triple-negative breast cancer: Implications for patient care. Current Problems in Cancer, 2016, 40, 130-140.	1.0	24
210	Equivalent survival after nipple-sparing compared to non-nipple-sparing mastectomy: data from California, 1988â€“2013. Breast Cancer Research and Treatment, 2016, 160, 333-338.	1.1	5
211	Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population. Cancer Causes and Control, 2016, 27, 1127-1138.	0.8	48
212	Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?. Current Atherosclerosis Reports, 2016, 18, 72.	2.0	14
213	Statin use and all-cancer survival: prospective results from the Womenâ€™s Health Initiative. British Journal of Cancer, 2016, 115, 129-135.	2.9	80
214	Comprehensive spectrum ofBRCA1andBRCA2deleterious mutations in breast cancer in Asian countries. Journal of Medical Genetics, 2016, 53, 15-23.	1.5	82
215	Safety of multiplex gene testing for inherited cancer risk: Interim analysis of a clinical trial.. Journal of Clinical Oncology, 2016, 34, 1503-1503.	0.8	1
216	Association of ovarian cancer (OC) risk with mutations detected by multiple-gene germline sequencing in 95,561 women.. Journal of Clinical Oncology, 2016, 34, 5510-5510.	0.8	3

#	Article	IF	Citations
217	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 44-56.	1.8	12
218	Prevalence and predictors of second opinions from medical oncologists for early-stage breast cancer: Results from the iCanCare study.. Journal of Clinical Oncology, 2016, 34, 185-185.	0.8	0
219	Recurrence risk perception and quality of life after treatment of breast cancer.. Journal of Clinical Oncology, 2016, 34, 175-175.	0.8	1
220	Contralateral prophylactic mastectomy decision-making in the population-based iCanCare study of early-stage breast cancer patients.. Journal of Clinical Oncology, 2016, 34, 177-177.	0.8	0
221	Breast oncology precision medicine: Genomic testing and treatment at the population level.. Journal of Clinical Oncology, 2016, 34, 288-288.	0.8	1
222	Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2016, 34, 1010-1010.	0.8	0
223	Compliance with guidelines and factors associated with ordering the 21-gene breast cancer assay.. Journal of Clinical Oncology, 2016, 34, 6552-6552.	0.8	0
224	Relationship between rising bilateral mastectomy rates and increased use of neoadjuvant chemotherapy (NAC) in California, 1998-2012.. Journal of Clinical Oncology, 2016, 34, 1052-1052.	0.8	0
225	Clinical use of the 21-gene assay and patient experiences in early-stage breast cancer.. Journal of Clinical Oncology, 2016, 34, 6501-6501.	0.8	0
226	Yield of multiplex panel testing compared to expert opinion and validated prediction models.. Journal of Clinical Oncology, 2016, 34, 1509-1509.	0.8	0
227	Magnitude of invasive breast cancer (BC) risk associated with mutations detected by multiple-gene germline sequencing in 95,561 women.. Journal of Clinical Oncology, 2016, 34, 1512-1512.	0.8	0
228	Dissemination of 21-gene assay testing among female breast cancer patients in the US.. Journal of Clinical Oncology, 2016, 34, 6553-6553.	0.8	0
229	Determinants of Patient Choice of Health Care Providers for Breast Cancer Treatment. Journal of Patient-centered Research and Reviews, 2016, 3, 174-175.	0.6	0
230	Breast Cancer Risk Reduction, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 880-915.	2.3	52
231	Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer. Breast Cancer Research, 2015, 17, 108.	2.2	19
232	Racial/Ethnic and Socioeconomic Differences in Short-Term Breast Cancer Survival Among Women in an Integrated Health System. American Journal of Public Health, 2015, 105, 938-946.	1.5	49
233	Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. Current Opinion in Obstetrics and Gynecology, 2015, 27, 23-33.	0.9	33
234	Multiple-Gene Panels and the Future of Genetic Testing. Current Breast Cancer Reports, 2015, 7, 98-104.	0.5	1

#	Article	IF	Citations
235	Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1039-1045.	1.1	95
236	Reply to S.M. Sorscher and A.B. Hafeez Bhatti. Journal of Clinical Oncology, 2015, 33, 4233-4233.	0.8	0
237	A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. Journal of Molecular Diagnostics, 2015, 17, 533-544.	1.2	167
238	Navigating choices when applying multiple imputation in the presence of multi-level categorical interaction effects. Statistical Methodology, 2015, 27, 82-99.	0.5	4
239	Intersection of Race/Ethnicity and Socioeconomic Status in Mortality After Breast Cancer. Journal of Community Health, 2015, 40, 1287-1299.	1.9	53
240	Treatment Decision Making and Genetic Testing for Breast Cancer. JAMA - Journal of the American Medical Association, 2015, 314, 997.	3.8	29
241	History of Recreational Physical Activity and Survival After Breast Cancer. American Journal of Epidemiology, 2015, 181, 944-955.	1.6	20
242	Multigene Panel Testing in Oncology Practice. JAMA Oncology, 2015, 1, 277.	3.4	68
243	Concerns About Cancer Risk and Experiences With Genetic Testing in a Diverse Population of Patients With Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1584-1591.	0.8	88
244	Diabetes and Other Comorbidities in Breast Cancer Survival by Race/Ethnicity: The California Breast Cancer Survivorship Consortium (CBCSC). Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 361-368.	1.1	62
245	How can we best respect patient autonomy in breast cancer treatment decisions?. Breast Cancer Management, 2015, 4, 53-64.	0.2	31
246	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutationâ€“Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. Journal of Clinical Oncology, 2015, 33, 1895-1901.	0.8	200
247	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncology, 2015, 1, 943.	3.4	294
248	Precision Medicine in Breast Cancer Care. JAMA Oncology, 2015, 1, 1109.	3.4	8
249	Contribution of the Neighborhood Environment and Obesity to Breast Cancer Survival: The California Breast Cancer Survivorship Consortium. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1282-1290.	1.1	29
250	Lymphopenia after adjuvant radiotherapy (RT) to predict poor survival in triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, 1069-1069.	0.8	10
251	Clinical impact of multi-gene panel testing for hereditary breast and ovarian cancer risk assessment.. Journal of Clinical Oncology, 2015, 33, 1513-1513.	0.8	1
252	Genetic testing decisions of breast cancer patients: Results from the iCanCare study.. Journal of Clinical Oncology, 2015, 33, 1541-1541.	0.8	2

#	Article	IF	Citations
253	Statin use and all-cancer mortality: Prospective results from the Womenâ€™s Health Initiative.. Journal of Clinical Oncology, 2015, 33, 1506-1506.	0.8	2
254	Addressing lack of US insurance coverage of Cancer Hereditary Multiplex Testing (CHMT).. Journal of Clinical Oncology, 2015, 33, e17515-e17515.	0.8	0
255	Contralateral prophylactic mastectomy decision-making in the population-based iCanCare study of early-stage breast cancer patients: Knowledge and physician influence.. Journal of Clinical Oncology, 2015, 33, 1011-1011.	0.8	2
256	Prevalence and consequences of second opinions from medical oncologists for early-stage breast cancer: Results from the iCanCare study.. Journal of Clinical Oncology, 2015, 33, 6508-6508.	0.8	0
257	Breast cancer treatment across health care systems: Linking electronic medical records and state registry data to enable outcomes research. Cancer, 2014, 120, 103-111.	2.0	48
258	Use of and Mortality After Bilateral Mastectomy Compared With Other Surgical Treatments for Breast Cancer in California, 1998-2011. JAMA - Journal of the American Medical Association, 2014, 312, 902.	3.8	221
259	Obesity and Mortality After Breast Cancer by Race/Ethnicity: The California Breast Cancer Survivorship Consortium. American Journal of Epidemiology, 2014, 179, 95-111.	1.6	90
260	Beyond barriers: fundamental â€˜disconnectsâ€™ underlying the treatment of breast cancer patients' sexual health. Culture, Health and Sexuality, 2014, 16, 1169-1180.	1.0	23
261	Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment. Journal of Clinical Oncology, 2014, 32, 2001-2009.	0.8	442
262	Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1326-1338.	2.3	119
263	Use of the 21-gene recurrence score assay (RS) and chemotherapy (CT) across health care (HC) systems.. Journal of Clinical Oncology, 2014, 32, 6580-6580.	0.8	0
264	Chromosomal copy number alterations (CNAs) for risk assessment of ductal carcinoma in situ (DCIS).. Journal of Clinical Oncology, 2014, 32, 565-565.	0.8	0
265	The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival. Cancer Causes and Control, 2013, 24, 1821-1836.	0.8	47
266	A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Research and Treatment, 2013, 142, 389-398.	1.1	29
267	The California Breast Density Information Group: A Collaborative Response to the Issues of Breast Density, Breast Cancer Risk, and Breast Density Notification Legislation. Radiology, 2013, 269, 887-892.	3.6	90
268	Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004â€“2007. Breast Cancer Research and Treatment, 2013, 137, 247-260.	1.1	37
269	Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. Familial Cancer, 2013, 12, 65-73.	0.9	11
270	Information Technology Interventions to Improve Cancer Care Quality: A Report From the American Society of Clinical Oncology Quality Care Symposium. Journal of Oncology Practice, 2013, 9, 142-144.	2.5	5

#	Article	IF	Citations
271	A Population-Based Observational Study of First-Course Treatment and Survival for Adolescent and Young Adult Females with Breast Cancer. Journal of Adolescent and Young Adult Oncology, 2013, 2, 95-103.	0.7	19
272	A Young Woman With Bilateral Breast Cancer: Identifying a Genetic Cause and Implications for Management. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 512-517.	2.3	3
273	Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis. PLoS ONE, 2012, 7, e43994.	1.1	93
274	Patient, Hospital, and Neighborhood Factors Associated with Treatment of Early-Stage Breast Cancer among Asian American Women in California. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 821-834.	1.1	18
275	Age-Specific Incidence of Breast Cancer Subtypes: Understanding the Blackâ€“White Crossover. Journal of the National Cancer Institute, 2012, 104, 1094-1101.	3.0	197
276	Reply to D.G. Evans et al. Journal of Clinical Oncology, 2012, 30, 1143-1144.	0.8	1
277	A Simulation Model to Predict the Impact of Prophylactic Surgery and Screening on the Life Expectancy of BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1066-1077.	1.1	43
278	Online Tool to Guide Decisions forBRCA1/2Mutation Carriers. Journal of Clinical Oncology, 2012, 30, 497-506.	0.8	81
279	Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Research, 2012, 14, R55.	2.2	196
280	Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients. Breast Cancer Research and Treatment, 2012, 136, 931-933.	1.1	14
281	Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. Familial Cancer, 2012, 11, 429-439.	0.9	27
282	Genetic Polymorphisms as Predictors of Breast Cancer Risk. Current Breast Cancer Reports, 2012, 4, 232-239.	0.5	1
283	Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLoS ONE, 2012, 7, e33788.	1.1	475
284	Accuracy of BRCA1/2ÂMutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort. World Journal of Surgery, 2012, 36, 702-713.	0.8	19
285	Oncoshare: lessons learned from building an integrated multi-institutional database for comparative effectiveness research. AMIA ... Annual Symposium proceedings, 2012, 2012, 970-8.	0.2	19
286	A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer. Annals of Surgical Oncology, 2011, 18, 2594-2598.	0.7	84
287	Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Research and Treatment, 2011, 127, 471-478.	1.1	140
288	Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: Findings From the Breast Cancer Family Registry. Journal of Clinical Oncology, 2011, 29, 4505-4509.	0.8	38

#	Article	IF	Citations
289	Genetic/Familial High-Risk Assessment: Breast and Ovarian. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 562-594.	2.3	253
290	High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients. Breast Cancer Research and Treatment, 2010, 122, 605-607.	1.1	5
291	Survival Analysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers. Journal of Clinical Oncology, 2010, 28, 222-231.	0.8	217
292	Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California. Journal of Clinical Oncology, 2010, 28, e155-e157.	0.8	53
293	Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Research, 2010, 12, R99.	2.2	139
294	BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Current Opinion in Obstetrics and Gynecology, 2010, 22, 72-78.	0.9	170
295	Identification and Management of Women at High Familial Risk for Breast Cancer. , 2010, , 135-145.		0
296	Second Primary Breast Cancer Occurrence According to Hormone Receptor Status. Journal of the National Cancer Institute, 2009, 101, 1058-1065.	3.0	114
297	Performance of Prediction Models for BRCA Mutation Carriage in Three Racial/Ethnic Groups: Findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1084-1091.	1.1	66
298	The decline in breast cancer incidence: Real or imaginary?. Current Oncology Reports, 2009, 11, 21-28.	1.8	16
299	Statins may reduce breast cancer risk, particularly hormone receptor-negative disease. Current Breast Cancer Reports, 2009, 1, 148-156.	0.5	13
300	Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Familial Cancer, 2008, 7, 179-186.	0.9	63
301	Magnetic Resonance Galactography: a Feasibility Study in Women with Prior Atypical Breast Duct Cytology. Breast Journal, 2008, 14, 211-214.	0.4	4
302	Performance ofBRCA1/2Mutation Prediction Models in Asian Americans. Journal of Clinical Oncology, 2008, 26, 4752-4758.	0.8	57
303	CDH1 Truncating Mutations in the E-Cadherin Gene. Annals of Surgery, 2007, 245, 873-879.	2.1	157
304	A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neuâ€"Positive Breast Cancer. Journal of Clinical Oncology, 2007, 25, 634-641.	0.8	115
305	Ductal Pattern Enhancement on Magnetic Resonance Imaging of the Breast Due to Ductal Lavage. Breast Journal, 2007, 13, 281-286.	0.4	5
306	A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. Cancer Genetics and Cytogenetics, 2007, 179, 89-92.	1.0	14

#	Article	IF	Citations
307	Biomedical terahertz imaging with a quantum cascade laser. Applied Physics Letters, 2006, 88, 153903.	1.5	133
308	Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging. JAMA - Journal of the American Medical Association, 2006, 295, 2374.	3.8	240
309	Comparative Analysis of Bio-Medical Imaging at 3.7 Terahertz with a High Power Quantum Cascade Laser. , 2006, , .		0
310	Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. Health Expectations, 2005, 8, 221-233.	1.1	18
311	Histologic types of epithelial ovarian cancer: have they different risk factors?. Gynecologic Oncology, 2005, 96, 520-530.	0.6	143
312	Ductal Lavage of Fluid-Yielding and Non-Fluid-Yielding Ducts in BRCA1 and BRCA2 Mutation Carriers and Other Women at High Inherited Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1082-1089.	1.1	27
313	Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. Cancer, 2004, 100, 479-489.	2.0	77